Cargando…

Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment

A 69‐year‐old Japanese male with advanced lung adenocarcinoma developed neurological symptoms after chemoradiotherapy and durvalumab maintenance therapy. He was positive for serum antiamphiphysin antibody, which is rarely seen in patients with lung adenocarcinoma. Additionally, his brain magnetic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwanaga, Yuto, Kawaguchi, Takako, Yamasaki, Kei, Sato, Tomoki, Kubo, Naoto, Morimoto, Toshiki, Isoshima, Yu, Sasahara, Yosuke, Orihashi, Takeshi, Yatera, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317590/
https://www.ncbi.nlm.nih.gov/pubmed/37253448
http://dx.doi.org/10.1111/1759-7714.14933
_version_ 1785067898344046592
author Iwanaga, Yuto
Kawaguchi, Takako
Yamasaki, Kei
Sato, Tomoki
Kubo, Naoto
Morimoto, Toshiki
Isoshima, Yu
Sasahara, Yosuke
Orihashi, Takeshi
Yatera, Kazuhiro
author_facet Iwanaga, Yuto
Kawaguchi, Takako
Yamasaki, Kei
Sato, Tomoki
Kubo, Naoto
Morimoto, Toshiki
Isoshima, Yu
Sasahara, Yosuke
Orihashi, Takeshi
Yatera, Kazuhiro
author_sort Iwanaga, Yuto
collection PubMed
description A 69‐year‐old Japanese male with advanced lung adenocarcinoma developed neurological symptoms after chemoradiotherapy and durvalumab maintenance therapy. He was positive for serum antiamphiphysin antibody, which is rarely seen in patients with lung adenocarcinoma. Additionally, his brain magnetic resonance images showed limbic encephalitis which led to the diagnosis of classic paraneoplastic neurological syndrome (PNS). Immune checkpoint inhibitors (ICIs) activate T cells and may also activate antineuronal antibodies that cause PNS. Durvalumab, which is an ICI, may have led to antiamphiphysin antibody‐positive PNS in our patient. Treatment with systemic high‐dose methylprednisolone was unsuccessful and he died 2 months later. PNS should be considered as one of the differential diagnoses in patients with lung cancer and neurological symptoms during, or after, ICI treatment.
format Online
Article
Text
id pubmed-10317590
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-103175902023-07-04 Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment Iwanaga, Yuto Kawaguchi, Takako Yamasaki, Kei Sato, Tomoki Kubo, Naoto Morimoto, Toshiki Isoshima, Yu Sasahara, Yosuke Orihashi, Takeshi Yatera, Kazuhiro Thorac Cancer Case Reports A 69‐year‐old Japanese male with advanced lung adenocarcinoma developed neurological symptoms after chemoradiotherapy and durvalumab maintenance therapy. He was positive for serum antiamphiphysin antibody, which is rarely seen in patients with lung adenocarcinoma. Additionally, his brain magnetic resonance images showed limbic encephalitis which led to the diagnosis of classic paraneoplastic neurological syndrome (PNS). Immune checkpoint inhibitors (ICIs) activate T cells and may also activate antineuronal antibodies that cause PNS. Durvalumab, which is an ICI, may have led to antiamphiphysin antibody‐positive PNS in our patient. Treatment with systemic high‐dose methylprednisolone was unsuccessful and he died 2 months later. PNS should be considered as one of the differential diagnoses in patients with lung cancer and neurological symptoms during, or after, ICI treatment. John Wiley & Sons Australia, Ltd 2023-05-30 /pmc/articles/PMC10317590/ /pubmed/37253448 http://dx.doi.org/10.1111/1759-7714.14933 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Iwanaga, Yuto
Kawaguchi, Takako
Yamasaki, Kei
Sato, Tomoki
Kubo, Naoto
Morimoto, Toshiki
Isoshima, Yu
Sasahara, Yosuke
Orihashi, Takeshi
Yatera, Kazuhiro
Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
title Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
title_full Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
title_fullStr Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
title_full_unstemmed Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
title_short Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
title_sort fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317590/
https://www.ncbi.nlm.nih.gov/pubmed/37253448
http://dx.doi.org/10.1111/1759-7714.14933
work_keys_str_mv AT iwanagayuto fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT kawaguchitakako fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT yamasakikei fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT satotomoki fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT kubonaoto fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT morimototoshiki fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT isoshimayu fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT sasaharayosuke fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT orihashitakeshi fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment
AT yaterakazuhiro fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment